Clinical trial Recruiting at 1 site Observational Ages 20 to 65

How genetic differences affect leflunomide response in Pakistani rheumatoid arthritis patients

Official title: Pharmacogenetics of Leflunomide in the RA Management

Run by Foundation University Islamabad · NCT07388407 · Data updated 2026-11-12

This project will test whether specific genetic variants (SNPs) predict how well leflunomide works and whether it causes side effects in Pakistani adults with rheumatoid arthritis.

Quick facts

Study typeObservational
Ages20 Years to 65 Years
SexAll
Enrollment110 (estimated)
SponsorFoundation University Islamabad
Academic / other
Drugs / interventionsmethotrexate
Locations2 sites (Islamabad, Punjab Province and 1 other locations)
StatusRecruiting
StartedSeptember 1, 2024
Main results expectedJune 30, 2026
Study endsSeptember 30, 2026
Registry record updatedFebruary 5, 2026
Trial IDNCT07388407 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 20–75 of Pakistani origin with rheumatoid arthritis who are starting leflunomide as the sole DMARD (with or without steroids), can consent, and can provide blood samples are the intended participants.

Probably not a fit

People who are not Pakistani, are taking other DMARDs, have significant renal or liver impairment, are pregnant or lactating, have active infections, or cannot complete three months of leflunomide therapy are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll Pakistani adults with rheumatoid arthritis who are starting leflunomide as their only DMARD or have been on it for less than a month. Participants will give a blood sample for DNA extraction and be followed across two visits three months apart while clinicians record disease activity (DAS28), ultrasound findings, and laboratory markers including ESR, CRP, anti-CCP, and liver tests. SNPs will be identified in the laboratory and correlated with measures of efficacy and toxicity using the collected clinical and biochemical data. The investigators plan to use these correlations to build an algorithm tailored to Pakistani RA patients to help guide leflunomide use.

Why it matters

Potential benefit: If successful, this work could help doctors predict which patients are likely to benefit from leflunomide and which are at higher risk of side effects, enabling more personalized treatment.

How similar studies have gone: Pharmacogenetic work on leflunomide and related drugs has reported some SNP associations with drug levels and toxicity but findings are limited and not yet definitive or widely implemented.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10
* Pakistani individuals
* between ages of 20-75 years
* New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available

Exclusion Criteria:

* Patients not willing to participate/ consent not given
* Patients below the age of 20
* Non- Pakistani origin
* Taking another DMARD simultaneously
* Compromised renal and hepatic functions
* Cognitive impairment, neurological disease
* Pregnant/ lactating patients
* Patients having inflammatory bowel disease/ Irritable bowel syndrome
* Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy-

Where it's running

  • Fauji Foundation Hospital, Rawalpindi
    Rawalpindi, Punjab Province, Pakistan
    Recruiting
  • Shifa International Hospital
    Islamabad, Punjab Province, Pakistan
    Completed

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.